Source BioScience PLC Director/PDMR Shareholding (4643Y)
September 08 2015 - 1:20PM
UK Regulatory
TIDMSBS
RNS Number : 4643Y
Source BioScience PLC
08 September 2015
8 September 2015
Source BioScience plc
(the 'Company')
Exercise of Share Options and Directors' Dealings
Source BioScience plc (LSE: SBS) announces that on 7 September
it issued and allotted 3,878,854 new ordinary shares of 2 pence
each in the Company (the 'New Ordinary Shares'), representing 1.11%
of its enlarged issued share capital, following the net exercise of
share options by certain Directors and other option holders under
the Source BioScience plc Share Option Schemes at an effective net
exercise price of nil.
As a result of the net exercise of share options:
-- Mr Laurence Turnbull, Chairman was allotted 2,041,667 New
Ordinary Shares in full settlement of his 2007 share option awards
which totalled 3,750,000 share options
-- Dr Nick Ash, Chief Executive Officer was allotted 1,454,243
New Ordinary Shares in full settlement of his 2006 and 2007 share
option awards which totalled 2,500,000 share options
-- Dr Nick Leaves, Chief Operating Officer was allotted 265,152
New Ordinary Shares in full settlement of his 2007 share option
awards which totalled 500,000 shares
The Company also announces that it was notified on 7 September
2015 that, following the exercise of share options, Mr Turnbull
sold 2,041,667 Ordinary Shares; Dr Ash sold 1,454,243 Ordinary
Shares and Dr Leaves sold 265,152 Ordinary Shares, all at 16.50p
per Ordinary Share on 7 September 2015. Following the exercise of
share options and the sale of Ordinary Shares, the number of
Ordinary Shares held by each Director remains unchanged.
Application has been made for the New Ordinary Shares to be
admitted to the Official List of the UK Listing Authority and to
trading on the Main Market of the London Stock Exchange. It is
expected that admission of the New Ordinary Shares will occur on or
around 8 September 2015
Following the issue and allotment, the Company's issued share
capital will comprise 349,100,255 ordinary shares of 2 pence each,
which figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or change to their interest in, Source
BioScience plc under the FSA's Disclosure and Transparency Rules.
The New Ordinary Shares will rank pari passu with the existing
Ordinary Shares and no Ordinary Shares are held in treasury.
This notification is provided in accordance with
DTR3.1.4R(1).
--- ENDS ---
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO and Company Secretary
Tel: +44 (0)115 973 9010
Email: enquiries@sourcebioscience.com
www.sourcebioscience.com
N+1 Singer (Financial Advisor, Sponsor and Broker)
Aubrey Powell/James White
Tel: +44 (0)207 496 3000
www.n1singer.com
About Source BioScience
Source BioScience plc (LSE: SBS) is a trusted provider of state
of the art laboratory services and products to the healthcare and
clinical, life and applied sciences and biopharma industries. It is
an international business operating ten state of the art facilities
in five countries and with customers in over 90 countries
worldwide. The Group offers a complementary portfolio of laboratory
services and products that share common technologies, laboratory
processes, infrastructure and expertise. These include clinical
diagnostics, genomics, proteomics, drug discovery and development
research as well as controlled environment storage and testing
services for a diverse range of markets. These services and
products are provided to a large and diverse customer base
including the top 50 pharmaceutical companies, leading universities
and research institutes worldwide, the UK NHS and other healthcare
providers. The Group is listed on the Premium Main Market of the
London Stock Exchange.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSSSMFWAFISEFU
(END) Dow Jones Newswires
September 08, 2015 13:20 ET (17:20 GMT)
Medical Solutions (LSE:MLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medical Solutions (LSE:MLS)
Historical Stock Chart
From Jul 2023 to Jul 2024